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Introduction: The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ), tau and phosphorylated tau (p-tau181) are
now used for the diagnosis of Alzheimer’s disease (AD). Aβ40 is the most abundant Aβ peptide isoform in the CSF,
and the Aβ 42/40 ratio has been proposed to better reflect brain amyloid production. However, its additional value
in the clinical setting remains uncertain.
Methods: A total of 367 subjects with cognitive disorders who underwent a lumbar puncture were prospectively
included at three French memory centers (Paris-North, Lille and Montpellier; the PLM Study). The frequency of
positive, negative and indeterminate CSF profiles were assessed by various methods, and their adequacies with the
diagnosis of clinicians were tested using net reclassification improvement (NRI) analyses.
Results: On the basis of local optimum cutoffs for Aβ42 and p-tau181, 22% of the explored patients had indeterminate
CSF profiles. The systematic use of Aβ 42/40 ratio instead of Aβ42 levels alone decreased the number of indeterminate
profiles (17%; P = 0.03), but it failed to improve the classification of subjects (NRI = −2.1%; P = 0.64). In contrast, the
use of Aβ 42/40 ratio instead of Aβ42 levels alone in patients with a discrepancy between p-tau181 and Aβ42 led
to a reduction by half of the number of indeterminate profiles (10%; P < 0.001) and was further in agreement with
clinician diagnosis (NRI = 10.5%; P = 0.003).
Conclusions: In patients with a discrepancy between CSF p-tau181 and CSF Aβ42, the assessment of Aβ 42/40
ratio led to a reliable biological conclusion in over 50% of cases that agreed with a clinician’s diagnosis.Introduction
Dementia is a growing public health concern in aging
populations. The number of people affected worldwide
is set to reach 66 million by 2030 [1]. Alzheimer’s
disease (AD) is the most frequent cause of dementia in
the elderly. Clinical diagnosis is based on the presence of
clinical symptoms, marked by a gradual onset of demen-
tia in the presence of cognitive decline, when other puta-
tive disorders have been excluded [2]. Unfortunately, the* Correspondence: julien.dumurgier@inserm.fr
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vation is associated with poor specificity. In most studies
comparing clinical diagnosis with neuropathological
findings, researchers have reported specificity lower than
70% [3]. Development of specific disease-modifying drugs
and early diagnosis require an improvement in the accur-
acy of AD diagnosis.
The use of biomarkers has strengthened the link
between clinical dementia and AD pathophysiology
[2]. Currently, cerebrospinal fluid (CSF) biomarkers are
commonly used in specialized memory clinics [4]. A
characteristic feature of AD progression is a reduction
in amyloid-β (Aβ) protein (that is, low CSF Aβ42 level)
and an increase of neuronal degeneration biomarkers
(that is, increase of CSF total tau and phosphorylatedtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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The decrease in CSF Aβ42 levels appears to be an early
phenomenon in AD progression and is evident over two
decades prior to the first clinical sign [6]. Unfortunately,
because CSF Aβ42 levels can also be low in non-AD
patients, this biomarker alone is of limited use in a clin-
ical setting [7,8]. The limited use of CSF biomarkers can
lead to indeterminate results, revealing abnormal tau
protein values and normal Aβ peptide levels or the in-
verse [2]. Furthermore, CSF biomarker results are also
characterized by a large intersite variability [7] that
requires the use of internally validated cutoff levels for
each laboratory [9].
Aβ40 is the most abundant Aβ peptide isoform in the
CSF. Compared with CSF Aβ42 levels alone, Aβ 42/40
ratio is suggested to account for the constitutive interin-
dividual differences in total CSF Aβ peptide load be-
tween high- and low-amyloid-producing individuals [10].
The Aβ 42/40 ratio could also play an important role in
Alzheimer’s disease pathogenesis [11]. However, the
added value of the CSF Aβ40 level assessment remains
controversial [12-15]. Recently, in a monocentric study,
researchers reported that CSF Aβ 42/40 ratio may be of
particular use in patients with ambiguous CSF results
[16]. Therefore, the goal of our present study was to
assess CSF Aβ 42/40 ratios and CSF Aβ42 levels alone to
discriminate AD from non-AD patients in a large,
prospective, multicentric population of patients. We
hypothesized that the use of Aβ 42/40 ratio would re-
duce the frequency of inconclusive CSF results and
would lead to a valid AD diagnosis.
Methods
Subjects
According to national recommendations, CSF analyses
are routinely used during testing of patients with cogni-
tive disorders in French memory centers [4,17]. Patients
were recruited between 1 September 2012 and 1 September
2013 from three French clinical and research memory
centers specializing in the care of patients with cogni-
tive disorders. These three centers are based in Paris,
Lille and Montpellier (the PLM Study) [18-20]. All
patients who were prospectively included in the study
had cognitive disorders and received a lumbar puncture.
Patients with unknown clinical diagnoses were ex-
cluded. Patients with mild cognitive impairment (MCI)
represented a heterogeneous group, including patients
with and without AD-related brain lesions, and thus
were excluded from this study.
All patients had a thorough examination, including
clinical and neuropsychological evaluations, biological
measurements and brain imaging. Patients with AD were
included according to the criteria for probable AD as
defined by the National Institute on Aging-Alzheimer’sAssociation [2]. On the basis of all available elements,
which included the results for CSF biomarkers, patients
were classified into two groups: AD and non-AD. Com-
plex or unclear cases were discussed, and diagnoses
were made by a multidisciplinary team of neurologists,
geriatricians and neuropsychologists. Non-AD subjects
included subjects with cognitive disorders other than
AD (see Additional file 1), such as frontotemporal demen-
tia, Lewy body disease, Parkinson’s disease, Creutzfeldt-
Jakob disease and non-degenerative dementia (that is
vascular dementia, alcohol-related dementia, normal
pressure hydrocephalus, infectious disease and psychi-
atric disorders) [7].
This research study was approved by the local ethics
committees of each hospital (see Additional file 2). All
patients agreed to CSF collection, assessments and ana-
lyses by providing a written informed consent.
Cerebrospinal fluid analysis
Lumbar punctures were performed on fasting patients
within 1 month following their clinical diagnosis, usually
between 9:00 am and 12:00 PM. In an effort to reduce
the intersite variability in CSF readings previously re-
ported [7], all three centers used a common 10-ml poly-
propylene tube to collect the CSF (catalog number
62.610.201; Sarstedt, Nümbrecht, Germany) [21]. Each
CSF sample was transferred at 4°C to the corresponding
local laboratory within 4 hours after collection and was
then centrifuged at 1,000 g for 10 minutes at 4°C. A
small amount of CSF was used to perform routine
analyses, including total cell count, bacteriological exam-
ination and total protein and glucose levels. The CSF
was aliquoted in 0.5-ml polypropylene tubes and stored
at −80°C to await further analysis. CSF Aβ40, Aβ42, total
tau and p-tau181 were measured in each local laboratory
using a commercially available sandwich enzyme-linked
immunosorbent assay (INNOTEST; Fujirebio Europe
NV, Gent, Belgium) according to the manufacturer’s
instructions. Concentrations of total tau greater than
1,200 pg/ml were well above the detection limit and thus
were not recalculated after dilution because of the con-
straints in the procedure. The biological teams involved
in CSF analyses were blinded to the clinical diagnoses.
Cerebrospinal fluid cutoff determination and
interpretation
CSF cutoffs used in the analyses were determined on the
basis of the population included in the present study.
We computed both overall and local cutoff receiver
operating characteristic (ROC) curves using STATA soft-
ware (v10, StataCorp, College Station, TX, USA). ROC
curves were built for each biomarker by plotting sensi-
tivity and 1 − specificity to discriminate AD from non-
AD patients. Optimum cutoff values were determined
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sensitivity + specificity − 1) and lowest distance between
ROC plot and point (0.1). We checked that both
approaches led to similar findings, and the presented
results correspond to the highest Youden index. STATA
code used for the determination of optimum cutoff is
detailed in the Additional file 3.
CSF results were defined as negative (that is, CSF
p-tau181 below cutoff and CSF Aβ42 above cutoff ) or
positive (that is, CSF p-tau181 above cutoff and CSF
Aβ42 below cutoff ). An indeterminate CSF profile was
defined by the association of one positive biomarker
and one negative biomarker.
We chose to evaluate tau pathology based on CSF
p-tau181 levels alone because p-tau181 and total tau
levels were highly correlated in our sample (Pearson’s
correlation coefficient = 0.87). Furthermore, p-tau181 has
previously been reported to be more discriminant than
total tau [22]. Analyses based on total tau led to findings
and conclusions similar to those obtained with p-tau181.
Statistical analysis
The subjects’ characteristics are presented overall, by
diagnosis (AD vs. non-AD) and by CSF collection
centers. The various groups (diagnoses, centers) were
compared using analysis of variance for continuous vari-
ables and χ2 test for categorical variables.
We computed ROC curves to evaluate the capacity of
each CSF biomarker to discriminate AD from non-AD
subjects. Analyses were performed in the overall study
population and then stratified by centers. Optimum cut-
offs for each biomarker were defined using the highest
Youden index to discriminate in the best possible manner
AD from non-AD subjects, thus maximizing sensitivity
and specificity of the analyses based on ROC curve ana-
lyses. Then we used local optimum cutoffs for further
analysis because intersite differences were present.
To evaluate the interest of ratio Aβ 42/40 versus CSF
Aβ42 alone, we compared three methods to interpret
CSF results:
1. Method 1: interpretation based on CSF p-tau181 and
on CSF Aβ42
2. Method 2: interpretation based on CSF p-tau181 and
on Aβ 42/40 ratio
3. Method 3: a decisional algorithm based, in a first
step, on CSF p-tau181 and on CSF Aβ42. Then, in
case of discrepancy between p-tau181 and Aβ42, we
used, in a second step, the Aβ 42/40 ratio in place of
Aβ1–42
For all three methods, we first determined the percentage
of AD, non-AD and indeterminate biological CSF profiles.
Proportions of indeterminate profiles according to themethods were compared using the McNemar test. Then
we used a net reclassification improvement (NRI) method
to compare method 2 to method 1, and method 3 to
method 1, among AD patients and non-AD patients
(based on clinical diagnosis). Briefly, NRI is a statistical
tool used to assess improvement in model performance
offered by a new method of classification compared with a
reference method [23,24]. The NRI compares the fre-
quency of appropriate reclassification to inappropriate re-
classification with the use of a new model of classification.
The NRI is based on reclassification tables constructed
separately for participants with or without the interest
event (that is, diagnosis of AD or non-AD) and quantifies
the correct movement in categories, up for events and
down for non-events. Upward movement (up) is a change
into a higher category, and downward movement (down)
is a change into a lower category based on the new algo-
rithm. The NRI is calculated as follows:
NRI = P (up | event) ‐ P (down | event) + P (down | non ‐
event) ‐ P (up | non ‐ event) [23]
The null hypothesis for NRI = 0 was tested using Z-
statistics following McNemar asymptotic test for correlated
proportions [22]. We provide an Excel file (Microsoft,
Redmond, WA, USA) that allows the assessment of NRI
with its standard error and its P-value [24].
All resulting P-values were two-tailed, and P ≤ 0.05
was considered statistically significant. Statistical ana-
lyses were performed using STATA version 10 and SAS
version 9.2 (SAS Institute, Cary, NC, USA).
Results
In this study, we enrolled a total of 367 participants who
received a lumbar puncture between 1 September 2012
and 1 September 2013. The study was conducted at
three study centers (Paris, n = 82 subjects; Lille, n = 124
subjects; Montpellier, n = 161 subjects). The subjects’
characteristics are summarized in Table 1. Compared
with non-AD subjects, participants with AD were older,
were more likely to be female and had lower Mini Mental
State Examination scores. Furthermore, subjects with AD
had higher CSF tau and p-tau181 levels, lower CSF Aβ42
levels and lower CSF Aβ 42/40 ratios. CSF Aβ40 levels
tended to be higher in patients with AD compared with
non-AD patients (P = 0.06), but this relationship was
attenuated after adjustment for age and sex (P = 0.19).
The percentages of patients with AD across centers
ranged from 31% to 59% (Table 2). There were no
significant differences in age or sex between AD and
non-AD patients across the three sites. In patients with
AD, the Aβ 42/40 ratio was the only comparable
biomarker between the three sites, with a mean value
ranging from 4.4% to 4.9% (P = 0.39).
The results of ROC curve analysis comparing AD with
non-AD patients and optimum cutoffs are presented in








Age (yr), mean (SD) 65.9 (10.7) 67.9 (9.7) 64.5 (11.2) 0.002
Women, n (%) 190 (51.9) 97 (60.6) 93 (45.2) 0.003
MMSE, mean (SD) 22.2 (61.1) 20.3 (6.1) 23.6 (5.6) <0.001
CSF biomarkers (pg/ml), mean (SD)
Total tau 445.4 (334.8) 660.5 (349.5) 279.2 (202.9) <0.001
pTau-181 62.8 (37.2) 89.7 (38.7) 42.0 (17.6) <0.001
Aβ42 863.6 (357.3) 668.5 (297.3) 1,014.5 (325.9) <0.001
Aβ40 15,426.6 (8,630.6) 16,383.6 (8,761.3) 14,686.9 (8,475.4) 0.06
Aβ 42/40 0.068 (0.047) 0.047 (0.022) 0.084 (0.054) <0.001
aAβ, Amyloid-beta; AD, Alzheimer’s disease; CSF, Cerebrospinal fluid; MMSE, Mini Mental State Examination; SD, Standard deviation. bBy χ2 test or analysis
of variance.
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curve (AUC) values for the various biomarkers can be
used to discriminate between AD and non-AD patients.
Across all three centers, tau (AUC range, 0.77 to 0.96)
and p-tau181 levels (AUC range, 0.84 to 0.95) were more
useful than Aβ42 levels (AUC range, 0.74 to 0.82) for
AD diagnosis. Aβ 42/40 ratio outperformed Aβ42 inTable 2 Intercenter characteristicsa
Characteristics Center 1 (N = 82
AD patients
Number of subjects (%) 37 (45.1)
Age (yr), mean (SD) 68.9 (8.6)
Women, n (%) 27 (73.0)
MMSE, mean (SD) 18.6 (6.5)
CSF biomarkers, pg/ml, mean (SD)




Aβ 42/40 0.044 (0.018)
Non-AD patients
Number of subjects (%) 45 (54.9)
Age (yr), mean (SD) 63.3 (10.7)
Women, n (%) 17 (37.8)
MMSE, mean (SD) 23.7 (4.9)
CSF biomarkers (pg/ml), mean (SD)




Aβ 42/40 0.087 (0.024)
aAβ, Amyloid-beta; AD, Alzheimer’s disease; CSF, Cerebrospinal fluid; MMSE, Mini Me
Standard deviation. bBy χ2 test or analysis of variance.only one of the three centers, but not in the overall
population (AUC = 0.81). Optimum cutoffs for CSF
Aβ42 and for Aβ 42/40 ratio ranged from 737 pg/ml to
836 pg/ml and from 0.050 to 0.082, respectively.
Figure 1 illustrates the results of CSF biomarkers
in the overall population according to CSF Aβ42 and
CSF p-tau181 and per the global cutoffs based on the) Center 2 (n = 124) Center 3 (n = 161) P-valueb
73 (58.9) 50 (31.1) <0.001
67.0 (9.5) 68.5 (10.7) 0.54
39 (53.4) 31 (62.0) 0.14
19.5 (6.3) 22.8 (4.9) 0.003
774.2 (370.7) 539.6 (315.2) <0.001
101.5 (42.2) 80.0 (39.2) 0.002
603.2 (245.4) 772.5 (363.5) 0.008
13,426.8 (5,250.9) 20,814.3 (12,114.6) <0.001
0.049 (0.021) 0.045 (0.025) 0.39
51 (41.1) 111 (68.9) <0.001
64.4 (10.6) 65.0 (11.8) 0.70
20 (40.0) 56 (50.4) 0.25
20.9 (6.1) 24.7 (5.3) <0.001
283.8 (150.5) 308.6 (248.6) 0.01
46.2 (15.8) 40.8 (19.7) 0.14
987.0 (344.7) 1,039.3 (343.3) 0.50
11,161.0 (4,955.5) 17307.2 (9,952.7) <0.001
0.098 (0.041) 0.077 (0.066) 0.06
ntal State Examination; p-tau181, tau phosphorylated at threonine 181; SD,
Table 3 Area under the receiver operating characteristic curve and optimal value to discriminate subjects with
Alzheimer’s disease from those withouta
CSF biomarkers, pg/ml AUC (SE) Optimal value Sensitivity Specificity Youden index
Overall
Total tau 0.87 (0.02) 330 0.84 0.81 0.65
p-tau181 0.90 (0.02) 62 0.79 0.91 0.70
Aβ42 0.81 (0.02) 752 0.78 0.79 0.57
Aβ 42/40 0.81 (0.02) 0.055 0.73 0.78 0.51
Center 1
Total tau 0.96 (0.01) 300 0.95 0.96 0.91
pTau-181 0.95 (0.02) 58 0.86 0.91 0.77
Aβ42 0.81 (0.05) 814 0.84 0.80 0.64
Aβ 42/40 0.93 (0.03) 0.065 0.89 0.84 0.73
Center 2
Total tau 0.91 (0.03) 389 0.86 0.82 0.68
p-tau181 0.91 (0.03) 64 0.85 0.86 0.71
Aβ42 0.82 (0.04) 836 0.90 0.71 0.61
Aβ 42/40 0.87 (0.03) 0.082 0.90 0.67 0.57
Center 3
Total tau 0.77 (0.04) 343 0.74 0.77 0.51
p-tau181 0.84 (0.04) 62 0.72 0.92 0.64
Aβ42 0.74 (0.05) 737 0.70 0.80 0.50
Aβ 42/40 0.75 (0.04) 0.050 0.64 0.79 0.43
aAβ, Amyloid-beta; AUC, Area under the receiver operating characteristic curve; CSF, Cerebrospinal fluid; p-tau181, tau phosphorylated at threonine 181; SE,
Standard error.
Figure 1 Scatterplot of cerebrospinal fluid amyloid-β42 and phosphorylated tau values in the overall study population. Black dots
represent non-ambiguous cerebrospinal fluid (CSF) results (non-Alzheimer’s disease (non-AD) in the upper left quadrant, AD in the lower right
quadrant). Gray dots represent indeterminate CSF results. Cutoffs for amyloid-β42 (Aβ42) and phosphorylated tau (p-tau181) were calculated in
the overall population. Among the 367 patients, 83 (23%) had indeterminate CSF results.
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A total of 284 patients (77%) had determinate and
definitive results using CSF Aβ1–42 and CSF p-tau181
levels (non-AD profile or AD-type profile), and 83 par-
ticipants (23%) had indeterminate CSF results.
Figure 2 illustrates the biological interpretation of CSF
results according to three methods. (1) Interpretation
based on CSF p-tau181 and CSF Aβ42 cutoffs (method
1) leads to 82 patients (22.3%) with indeterminate
results. (2) Using CSF p-tau181 and Aβ 42/40 ratio
(method 2) could reduce the number of indeterminate
profiles to 64 patients (17.4%; P = 0.03 compared with
method 1). (3) Use of CSF p-tau181 and CSF Aβ42, and
then Aβ 42/40 ratio in case of discrepancy (method 3),
attenuated the number of indeterminate results to 38
patients (10.4%; P < 0.001 compared with method 1).
Figure 3 presents reclassification tables, comparing
method 1 with methods 2 and 3 in patients with AD and
non-AD patients. The systematic use of Aβ 42/40 ratio
did not improve the classification of patients and tended
even to be slightly worse than CSF Aβ42 alone with
a NRI equal to −2.1% (standard error (SE) = 0.05,
P = 0.64). By contrast, the use of Aβ 42/40 ratio only in
patients with discordant results between p-tau181 and
Aβ42 (method 3) improved the classification of patients,
with a NRI at 10.5% (SE = 0.04, P = 0.003) compared
with method 1.
Discussion
In this clinically based, multicenter study, we evaluated
the systematic assessment of CSF Aβ40 as part of a bat-
tery of CSF biomarkers measured in patients with cogni-
tive disorders. We made the following observations:Figure 2 Biological interpretation of cerebrospinal fluid results accord
phosphorylated tau (p-tau181) and CSF amyloid-β42 (Aβ42). Method 2: CSF
CSF Aβ42, then use of Aβ 42/40 ratio instead of Aβ42 in case of discrepanc
were compared using the McNemar test. The Aβ 42/40 ratio was the only biomarker that was
consistent between centers in AD and non-AD
patients. We may therefore hypothesize that this
ratio is less sensitive to preanalytical and analytical
conditions.
 The systematic use of Aβ 42/40 ratio instead of
Aβ42 decreased the number of indeterminate CSF
profiles but failed to improve the classification of
patients based on clinical diagnosis (NRI = −2.1%,
P = 0.64).
 A strategy based on the use of Aβ 42/40 ratio instead
of Aβ42 in patients with initially discrepant results
between p-tau181 and Aβ42 led to a reduction of
the number of indeterminate CSF profiles (10% vs.
22%) and improved the classification of patients
(NRI = 10.5%, P = 0.003).
Consequently, the assessment of Aβ 42/40 ratio could
be helpful and can be recommended as a second step
when the initial CSF profile remains indeterminate.
Researchers in several previous studies have investi-
gated the use of Aβ 42/40 ratio to differentiate patients
with AD from patients with other cognitive disorders,
and the reported results are heterogeneous. In a previ-
ous study, researchers found that Aβ 42/40 ratio outper-
formed Aβ42 alone in differentiating AD from non-AD
patients, but the diagnostic performance of the combin-
ation of CSF tau and CSF Aβ42 was not improved by
the use of Aβ 42/40 ratio instead of Aβ42 alone [15]. In
another study, using a subset of autopsy-confirmed diag-
noses, investigators found no overall difference in AUC
between Aβ 42/40 ratio and Aβ42 alone to differentiate
AD from non-AD patients. Those authors showed thating to different methods. Method 1: Cerebrospinal fluid (CSF)
p-tau181 and Aβ 42/40 ratio. Method 3: First measure p-tau181 and
y. Proportions of indeterminate profiles according to the methods
Figure 3 Reclassification tables of different methods of cerebrospinal fluid interpretation among patients with Alzheimer’s disease and
non-Alzheimer’s disease patients. Method 1 (reference): cerebrospinal fluid (CSF) phosphorylated tau (p-tau181) and CSF amyloid-β42 (Aβ42).
Method 2: CSF p-tau181 and Aβ 42/40 ratio. Method 3: First measure p-tau181 and CSF Aβ 42, then use Aβ 42/40 ratio instead of Aβ42 in case of
discrepancy. Cells in green indicate an improvement compared with method 1, and cells in red indicate a worsening.
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in patients with intermediate levels of phosphorylated
tau [12]. In other previous studies, researchers also
found that the assessment of CSF Aβ40 may help to
discriminate between AD patients and patients with
frontotemporal lobar degeneration [25] or dementia
with Lewy bodies [26] and Parkinson’s disease with de-
mentia [27]. In contrast, the authors of another previous
report found that the diagnostic accuracy of CSF Aβ42
was not different from the Aβ 42/40 ratio to discrimin-
ate AD patients from control subjects [14]. Controver-
sial data have also been reported in patients with MCI,
with some studies revealing that the Aβ 42/40 ratio may
be useful to predict dementia conversion [28], whereas
another did not [13].
Our findings confirm and strengthen the results of a
recent study in which researchers reported that the use
of the Aβ 42/40 ratio may contribute to decreases in the
proportion of indeterminate CSF profiles in the clinical
setting [16].
The proportion of patients with AD varied greatly at
the three centers, reflecting the differences in recruit-
ment and practices of memory clinics. Despite signifi-
cant intercenter differences in reporting CSF Aβ40 and
CSF Aβ42 levels, the mean Aβ 42/40 ratios were com-
parable across the three centers, ranging from 0.044 to
0.049 in patients with AD. We therefore hypothesize
that the use of the CSF amyloid ratio could contribute todecreased preanalytical and analytical sources of vari-
ability among centers. Interestingly, we found that
optimal cutoff for the ratio in the overall study popula-
tion was equal to 0.055, which was comparable to the
0.057 cutoff recently reported by another team in a
monocentric study [12].
Very few data are available concerning indeterminate
profiles of CSF biomarkers. In our study population, on
the basis of routine clinical practice, this situation was
not rare, being observed in 22% of the patients even
after optimization procedures using local optimum
cutoffs. We have shown that Aβ 42/40 ratio instead of
Aβ42 leads to a clear biological conclusion in more than
50% of these indeterminate cases. Reclassification ana-
lyses also showed that this approach is more congruent
with the diagnosis by clinicians.
This study has several strengths, including its large
size, its multicentric and prospective design, and the use
of a common CSF polypropylene tubing at each of the
three centers to standardize CSF evaluation. In addition,
we used a NRI method that compares different strategies
of biomarker analyses and is more precise than trad-
itional analyses based on ROC curves. The main limita-
tion of the results is the lack of neuropathological
validations. Also, clinicians were not blinded to CSF
results prior to clinical diagnosis, which may generate a
circular reasoning bias in our findings. The absence of a
centralized measurement for CSF biomarkers is another
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ability despite the use of a common tubing to collect
CSF. Furthermore, the non-AD group was heteroge-
neous and included patients with cognitive disorders, of
both psychiatric and neurologic origins. However, our
study was aimed at reflecting the standard practice at
memory clinics. The wide variety of patients with a
number of diseases reflects the broad spectrum of cogni-
tive complaints referred to memory centers. Finally, this
study excluded patients with MCI. Inclusion of these
patients in future studies will help to determine the links
between the amyloid ratio and the rate of conversion
from MCI to AD.
Conclusions
Using a large prospective multicenter cohort of patients
with cognitive disorders, we did not find an added value
for the systematic assessment of the CSF Aβ 42/40 ratio.
However, in cases of discrepancy between CSF p-tau and
CSF Aβ42, the use of Aβ 42/40 ratio allowed reaching a
biological conclusion in more than 50% of indeterminate
results and improved the biological congruence with
clinical diagnoses.
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